Trial NCT04412018
Publication Kosmopoulos A, iScience, 2021
Primary outcome on the report: Biomarker: unadjusted change in high-sensitivity C-reactive protein (hs-CRP) levels from baseline (day 1) to follow-up (day 14 + 3). Clinical: change in symptomatology as assessed by the InFLUenza Patient-Reported Outcome (FLU-PRO) score.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.